Introduction The World Health Organisation (WHO) has set ambitious goals to reduce the global disease burden associated with, and eventually eliminate, viral hepatitis. Objective To assist with achieving these goals and to inform the development of a national strategic plan for Malaysia, we estimated the long-term burden incurred by the care and management of patients with chronic hepatitis C virus (HCV) infection. We compared cumulative healthcare costs and disease burden under different treatment cascade scenarios. When including screening programme costs, the total cost was estimated at US$952 million, which was 12% higher than the estimated total cost of scenario C. Conclusions The scale-up to meet the WHO 2030 target may be achievable with appropriately high governmental commitment to the expansion of HCV screening to bring sufficient undiagnosed chronically infected patients into the treatment pathway. 
Introduction
The World Health Organisation (WHO) Global Health Sector Strategy (GHSS) for hepatitis has set ambitious goals to reduce the forecasted disease burden associated with chronic hepatitis C virus (HCV) infection and eventually eliminate the disease (by 2030) [1] . The action plan for the WHO Western Pacific Region (WPR), in which Malaysia is a participating country, includes plans for phased implementation of testing, treatment, and patient management services [2] and interim targets for diagnosis of 30% of chronically infected individuals and treatment of 50% of eligible patients by 2020. The corresponding WHO GHSS viral hepatitis targets for 2030 are 90% of chronically infected individuals diagnosed and 80% of eligible patients initiated on antiviral therapy, with a cure rate of 90%. The latter target depends on availability and delivery of treatment with all-oral direct-acting antivirals (DAAs).
Challenges in the timely expansion of service and care provision notwithstanding, a major hurdle to meeting the WHO treatment uptake targets using highly effective DAA therapies is affordability [3, 4] . In the Asian region, relatively few patients with HCV have received DAA treatment to date because of barriers to accessibility (i.e. availability or cost) and to entering the care pathway [5] . In Malaysia, recent governmental developments, namely the offer of a voluntary licensing agreement and the issuing of a compulsory license for sofosbuvir, will allow acquisition of DAAs at affordable prices.
Reducing the currently high disease burden for many Asian countries involves numerous obstacles. To assist in national strategic planning, model-based projections of both the HCV disease burden and the healthcare costs incurred in the management, care, and treatment of patients with chronic HCV are valuable [1] . Previous work developed a Markov model of the disease progression pathway of HCV-related liver disease for the Malaysian setting, and the disease burden was forecasted to the year 2039 assuming the best available standard of treatment: pegylated interferon/ribavirin (PegIFN/RBV) [6] . We extend this disease burden projection model, attaching disease-stage-specific healthcare costs to each patient-year, and adopting the much more effective and tolerable DAA treatment to project national-level annual HCV patient management and treatment costs.
The main objective of this paper is to estimate the future (long-term, 2018-2040) economic implications for the Malaysian healthcare system of managing patients with HCV. We compare the healthcare costs and disease burden in disability-adjusted life-years (DALYs) under four treatment cascade scenarios: (A) no treatment; (B) pre-2018 standard of care (PegIFN/RBV antiviral treatment), (C) all oral DAA treatment, with a gradual scale-up in annual treatment uptake that would not meet the WHO 2030 target; (D) DAA treatment with a scale-up in annual uptake to meet the 2030 target. The latter two scenarios assume that screening/diagnosis and treatment services could be sufficiently expanded to meet these targets. We combined the estimated costs for the expansion of screening with direct healthcare costs to arrive at a total cost to achieve the scale-up scenarios.
Methods

Model Description
We calculated and attached direct patient care costs to an HCV disease progression model developed for the Malaysian setting. As in previous modelling work, clinical progression from acute HCV infection through liver-related death was simulated using an age-structured multi-state Markov model [6] . We expanded our previous model with three additional compartments (Fig. 1) . Ethical approval and informed consent were not required for this modelling study.
The model disease states are acute infection (AI), recovered (R), chronic infection (CI), moderate chronic hepatitis (MCH), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) concurrent with CC, HCC concurrent with DC, and death from DC/HCC. MCH corresponds to Metavir stage F2-F3 (i.e. moderate/advanced fibrosis), and CC corresponds to Metavir stage F4. Two further states denote viral clearance through antiviral treatment but without recovery from liver disease: CC-RNA-and DC-RNA-. The model parameters that describe the flow between disease states (annual transition probabilities between compartments) and excess mortality rates due to non-liver-related causes were obtained from the literature (Table S1 in the Electronic Supplementary Material [ESM] ). Liver transplantation was not included as an additional pathway, as very few transplants are performed in patients with HCV in Malaysia.
Key Points for Decision Makers
World Health Organization (WHO) initiatives to greatly reduce the burden of hepatitis C virus (HCV) by 2030 have led many-mostly well-resourced-countries to update national treatment policies to include the new and highly effective direct-acting antiviral (DAA) therapies.
For the first time, we make available projections of the direct healthcare costs of HCV management under different treatment scenarios in Malaysia.
An enormous scale-up in screening activity and treatment uptake is needed to meet the WHO 2030 targets. Savings in care costs mean this scale-up is only moderately more expensive than a less steep scale-up strategy.
The model cycle length was set at 1 year, and the clinical progression of cohorts of acutely infected patients comprising 86 age groups was modelled, from < 1 year through 85 years of age. For simplicity, all simulated patients were assumed to die after the age of 85 years. The simulation start year was 1960 (i.e. HCV was assumed to circulate from 1960), and the model was run up to and including 2040. The annual number of new AIs was simulated using separate age distributions for people who inject drugs (PWID) and non-PWID risk groups (see McDonald et al. [6] ). Assumptions regarding HCV incidence over time were also adopted from the previous study (see the ESM).
Treatment Cascade Scenarios
Healthcare cost and disease burden projections will depend on the number of chronically infected patients initiated on treatment. We describe each of the four scenarios explored below. For all scenarios, the historical annual numbers of patients initiated on treatment nationally were estimated based on interferon sales (R. 
Genotype Distribution and Sustained Virologic Response (SVR) Rates
From data on patients who received antiviral therapy at Selayang Hospital between 2000 and 2014, the assumed genotype distribution was 64% G3 and 36% G1/other [7] . Sustained virologic response (SVR) rates for interferonbased treatment of 62% for G3 and 43% for G1/other from the Malaysian routine care setting were adopted [8] . For DAA treatment, we adopted intention-to-treat SVR rates for CI-and MCH-stage patients of 88% [9] and 94% [10] for G3 and G1/other, respectively. For patients with CC or DC, the SVR rate was set at 78% for all genotypes [11] .
Scenario A: No Treatment
We included scenario A, no treatment, as a baseline scenario to gauge the costs of care and management of patients with HCV-related liver disease alone.
Scenario B: Pre-2018 Standard of Care
We defined this scenario to quantify the difference in the total cost of care and treatment using DAAs and the previous standard of care using interferon therapy. Prior to 2018, 
Scenario C: DAA Treatment with Gradual Scale-Up in Treatment Uptake
Starting with 1500 patients treated with DAAs in 2018, this was increased by 500 per year throughout the rest of the simulation period. This scenario was devised on the basis of informal estimation of the annual increase that would allow expansion of screening and treatment services.
Scenario D: DAA Treatment with Scale-Up to Meet WHO Uptake Target
This scale-up to meet the WHO GHSS 2030 uptake target required a steep rise in the numbers of patients treated annually, from 5000 in 2018 to 30,000 in 2025-2028 and decreasing to 5000 patients per year initiated on treatment thereafter ( Fig. S3 in the ESM).
For scenarios C and D only, the estimated cost of a screening programme to deliver the required annual numbers of treated chronically infected patients [12] was incorporated to estimate the total economic burden. This stepwise strategy uses existing screening/diagnosis efforts as a starting point, followed by prioritised targeting of active and former PWID, with intensive general population screening as a final phase.
For the scenarios involving DAA treatment (C and D), treatments were distributed over disease stage according to the distribution at initial presentation at Selayang Hospital (the national tertiary care referral centre for liver disease) [7] . Treatment was only considered viable for patients without HCC. For scenario C, treatments were distributed among untreated patients in the pre-HCC states throughout the entire simulation period as follows: CI 22%, MCH 48%, CC 26%, DC 4%. For scenario D, this distribution was used for 2018-2022; from 2023 onwards, the anticipated effect of scaled-up screening reaching more early-stage patients was simulated by increasing the percentages of CI and MCH patients receiving treatment and reducing the percentages of CC and DC, settling on CI 53.25%, MCH 45.25%, CC 1.0%, and DC 0.5% in 2037-2040 ( Fig. S1 in the ESM). With respect to interferon-based therapy (scenario B; all scenarios pre-2018), treatments were distributed among pre-cirrhotic (69%; all assumed in MCH stage) and cirrhotic (31%; all CC stage) patients only; this distribution was based on Selayang Hospital data [7] .
Disability-Adjusted Life-Year (DALY) Computation
The composite DALY measure sums premature mortality (in years of life lost [YLL] ), calculated as the number of deaths multiplied by the remaining life expectancy at age of death, and morbidity (in years lived with disability [YLD]), calculated as the number of prevalent cases multiplied by the disability weight [13] . The DALY for chronic HCV infection is therefore the sum of the YLL and YLD associated with all disease states following AI in the progression model. We used the same disability weights as in the previous study [6, 14, 15] and adopted life expectancy values from the WHO Global Health Observatory [16] .
Patients Within Care and Patients Initiated on Treatment
As direct costs are attached only to patients in care, our projections require data on the annual numbers of patients in care within each disease stage (so costs associated with medical care and management can be estimated). We assumed that only symptomatic patients are in care and estimated that 15% of CI and MCH patients, 60% of CC-stage [17] , and 100% of DC-and HCC-stage patients are symptomatic. Of the symptomatic patients only, 10% of CI-and MCH-stage patients and 70, 100, and 100% of CC-, DC-, and HCC-stage patients, respectively, were assumed to be in care and therefore to incur costs (R. Mohamed, personal communication). For simplicity, we assumed that all referred patients incurred antiviral treatment costs, including those who did not start or complete treatment because of the following reasons: non-compliance/refusal, deemed unsuitable by physician, death, or loss to follow-up. As the SVR rates adopted were all from intention-to-treat study designs, we do not need to separately account for patients not completing therapy when calculating treatment costs.
To achieve the high WHO treatment uptake target of 80% of all eligible chronically infected individuals in 2030 (scenario D), a corresponding steep scale-up in the annual numbers of patients entering the treatment pathway is also required. A comparable scale-up in screening/diagnosis would also be needed to ensure sufficient individuals for the next step of the cascade (referred for treatment).
Calculation of Direct Healthcare Costs
We used the public payer perspective and calculated healthcare costs and resource use only. As our focus was on direct patient care/management costs, we excluded programme costs for screening and testing and the indirect costs of HCV disease; however, we did consider the estimated cost of an expanded screening programme (see Sect. 3.2). Future costs were inflation adjusted according to a rate of 2.5% (estimated based on recent Consumer Price Indices). All annualized costs are those within the public healthcare system, as most HCV treatment is performed within this system, although private healthcare options do exist in Malaysia. In view of highly subsidised public healthcare and given that the majority of HCV infections occur within economically disadvantaged populations such as PWID [18] , most HCV care is performed at public healthcare facilities. DAA costs were calculated based on estimated prices through competitive market pricing by government negotiations with voluntary license manufacturers for sofosbuvir and velpatasvir at 3000 Malaysian ringgit (RM) per 12-week course. Ribavirin was estimated at RM360 per week. See the ESM for further details on costing. Given recent announcements by the MMH of a RM1000 price tag for generic DAA under compulsory licensing to be provided to patients at 18 MMH hospitals [19] , we investigated the effect of lower DAA pricing via sensitivity analysis (see section 2.7).
Outcomes
Model outcomes for each year of the period 2018-2040 were (1) cumulative proportion of eligible patients initiated on treatment (to evaluate WHO targets) (see Eq. 1 below); (2) cumulative proportion of eligible patients achieving SVR (see Eq. 2); (3) total annualised costs per disease stage; (4) cumulative DALYs due to CI; and (5) percent reduction in annual projected deaths from DC/HCC compared with the annual modelled deaths in baseline year 2015. We defined 'eligible patients' as those living with chronic HCV infection. Note that the percentage of eligible patients treated required to meet the WHO WPR 2020 target of 30% of chronically infected patients diagnosed and 50% of diagnosed patients treated, is 15%. Similarly, for the WHO 2030 target year, the 90% diagnosed and 80% treated targets correspond to 72% (0.9 × 0.8) of eligible patients.
We now describe how outcomes (1) and (2) were calculated. The denominator of both Eqs. 1 and 2, TotalEligible, is defined as the model-estimated number of living chronically infected individuals in the year 2015 (n = 378,000; common to all four scenarios), and the numerator of each equation describes the cumulative number of treated patients (Eq. 1) or the cumulative number of patients achieving SVR (Eq. 2) between the year 2003 and year t. Outcome (v) was included to evaluate the WHO target for a reduction in HCV mortality. It is calculated simply as the projected number of deaths from DC/HCC in a given year of the simulation period divided by the number for the year 2015 (n = 1392).
One-Way Sensitivity Analysis
For scenario D only, we investigated the impact on total cost (period 2018-2030) from 20% lower or higher values for parameters treated as constants: AI incidence from 2016 and proportion of CI-, MCH-, and CC-stage patients who are symptomatic and in care. We also calculated the total cost assuming universally lower DAA prices (i.e. available for all patients, not just for the 18 MMH hospitals): RM1000 and an in-between value of RM2000.
Simulation Procedure
All model parameter values are summarised in Tables S1 and S2 in the ESM. The disease progression model was implemented and run using R version 3.2.0 [20] . Markov chain Monte Carlo (MCMC) sampling methods in a Bayesian framework were used to propagate uncertainty in model parameters to annual costs and DALY estimates. Sampling from the posterior distributions for each parameter was carried out via MCMC simulation using OpenBUGS version 2.2.2 [21] and the BRugs package for R [22] . We discarded 2000 MCMC samples as burn-in, with the next 2000 samples per chain forming the posterior distributions for all parameters.
Model Validation
Validation of the model using recently proposed criteria [23] was carried out by the research team, which comprised a modeller/epidemiologist, two hepatologists, and two health economists. Consensus on input data (costs, disease progression, and other model parameters) was achieved by considering the international literature and the Malaysian context. The costing methodology, including the perspective, time horizon, and calculation approach, were considered appropriate and to adhere to standard recommendations for health economic research. All costs were collected through primary data collection and reflect the financial implications of treating and managing HCV disease within the standard clinical pathway in Malaysia and recent WHO treatment guidelines. Face validity of the conceptual model, input data, and outcomes were also verified. Model code was checked for logical correctness by assuming a fixed size cohort of patients chronically infected with HCV and then enumerating the number of individuals progressing to each subsequent disease stage. Model outcomes could not be validated using alternative input data or against empirical data because suitable data were lacking. Compared with other disease stages, HCC concurrent with DC had the highest annual treatment cost because of the complex and costly clinical management required from both hepatology and hepatobiliary departments. The cost of DC alone was 31 times higher than that of managing precirrhotic disease stages.
Results
Direct Cost Estimates
Cost Forecasts
The annual number of patients initiated on antiviral treatment over the period 2018-2040 depends on the total number of treatments assumed and the distribution over disease stage (Fig. S1 in the ESM) . The number of patients eligible for treatment was set at the model-projected number of chronically infected patients in 2015: n = 378,000. The cumulative proportion of patients initiating treatment reached the WHO 2030 target (72% of total eligible patients) only in scenario D (Fig. S3 in the ESM) . However, the treatment scale-up in this scenario was inadequate to meet the WHO WPR interim target for 2020 of 15% (7.6% of total eligible patients were initiated on treatment by 2020; Table S3 in the ESM).
The estimated screening programme costs to deliver the needed annual numbers of chronically infected patients to be initiated on treatment for scenarios C and D were US$15 and 62 million [12] , respectively. The higher cost for scenario D is due to the extensive general population screening effort required. Table 2) . Although these two scenarios had the lowest projected cumulative direct costs for the period 2018-2030, this was offset by the 26 and 37% higher cumulative DALYs projected for scenarios C and A, respectively, compared with D (Table 2) .
Combining direct patient costs with screening programme costs, scenario D was 12% more expensive (US$952 vs. 847 million) than scenario C (Table 2) .
For the gradual scale-up scenario (C), annual direct costs were projected to increase 1.4-fold by 2040, from US$51 million [95% uncertainty interval (UI) 34-77] in 2018 to US$70 million (95% UI 47-113) in 2040. For scenario D, annual direct costs increased by approximately the same factor-1.5-fold-between 2018 and the observed peak in 2025 (i.e. a consequence of the peak annual number of treated patients, n = 30,000, being reached in 2025). The majority of the non-treatment costs (for the period 2018-2030) in scenarios B and C was for the management and care of patients in the CC, DC, and HCC stages: 95.5 and 91.2%, respectively; this was much smaller for scenario D, at 63.4%, due to advanced liver disease prevented. One-way sensitivity analyses conducted for scenario D indicated that the total cost for the period 2018-2030 was most sensitive to DAA pricing (Fig. S4 in the ESM). DAA prices of RM2000 and RM1000 reduced the median total cost by 9 and 18%, respectively.
In scenarios C and D, respectively, 9.5 and 38.7% of the cumulative direct healthcare costs to 2030 were for treatment. The WHO target of a 65% reduction in mortality by 2030, compared with baseline year 2015, was not achieved in any scenario (Table S3) 
Discussion
In this study, we projected the economic implications for the Malaysian healthcare system for the care and management of patients with HCV infection under various treatment cascade scenarios. Scenario D, which scaled up health service delivery to meet the WHO 2030 diagnosis and treatment uptake targets, incurred the largest burden (in direct costs) over the period 2018-2030: US$890 million (95% UI 653-1270), of which 39% was treatment-associated costs (including drugs). This scenario also had the largest estimated impact on population health, by averting 253,000 DALYs compared with the baseline scenario (B), the pre-2018 standard of care ( Table 2 ). The lower direct cost of the 'gradual scale-up' scenario (C) (US$832 million over 2018-2030; 95% UI 556-1259) was offset by a substantially smaller impact on the disease burden (72,000 DALYs averted over 2018-2030 compared with baseline scenario B). Considering patient care/management costs only, scenario D was only modestly more expensive than C, as the increased treatment costs for scenario D were almost completely compensated by savings in care costs. This was true even when screening programme costs were also included; the total economic burden for scenario D was only moderately higher (12%) than for C (Table 2) . This difference will diminish if DAA pricing is less expensive than assumed. Scenario D implements the projected enormous scaleup that would be required to meet the WHO 2030 treatment uptake target. We consider whether such a scale-up would be realistically achievable. Given that, in many countries with high diagnosis/treatment rates, < 5% of eligible patients have been initiated on treatment annually (estimates for the pre-DAA era [24] ), it is unclear whether a scale-up in Malaysia from an estimated 1.1% of eligible individuals in 2018 to 72% in 2030 is within the realm of possibility. In terms of annual numbers initiated on DAA therapy, Egypt-with a population three times that of Malaysia and much higher HCV prevalencehas made remarkable progress, treating 670,000 people between October 2014 and September 2016 [25] . With the advent of DAA therapies in Australia, an estimated 30,400-33,400 individuals were initiated on treatment between March and December 2016 [26] , which suggests that the annual uptake in our scenario D could be achievable with sufficient governmental commitment and resources. Affordability of DAA would appear to no longer be a fundamental constraint, as the cumulative costs of care and treatment under DAA are highly similar to cost projections under the pre-2018 standard of care.
For Malaysia-and other middle-income countries with endemic HCV-to meet the WHO 2030 targets, or at least to reduce the disease burden to the levels projected within our 'gradual scale-up' scenario C, many barriers must be overcome. Even if available at an affordable price, highly effective antiviral treatment is insufficient unless it can be delivered to those who need it (and are aware that a cure is possible). Expansion of HCV screening, disease assessment, and treatment services may be more challenging than lowering drug prices. It is notable that the assumed number of patients within care for scenario D is far lower than the number of DAA-treated patients required to meet the WHO 2030 target (Fig. S2 in the ESM) .
Diagnosis of 90% of all chronically infected individuals by 2030 requires an immense case-finding effort. Wellresourced countries that have intensively attempted this task by improving and scaling up ancillary and other screening programmes have not yet managed to diagnose more than about 80% of the chronically infected population (e.g. in Australia, 82% of living infected individuals were diagnosed by 2015 [27] ).
In Malaysia, 28% (25,700/90,603) of HIV-infected individuals were estimated to be in treatment and care (i.e. receiving antiretroviral treatment [ART]) in 2015 [28] . Given that patients with HCV overlap substantially with those with HIV in terms of behavioural risk factors-a large proportion is PWID, who have poor access to healthcare-and may share rationale for the decision not to proceed along the healthcare pathway after receiving a positive diagnosis (e.g. not feeling unwell, difficulty making appointments, anxiety about treatment side effects), the scaling-up of treatment uptake proposed in scenario C may be feasible. However, the estimated cumulative proportion of chronically infected HCV patients initiated on treatment needed to meet the WHO 2030 target is 72% (achieved only in scenario D), much larger than the estimated proportion of patients with HIV currently in contact with health services. This example from HIV suggests an important constraint on the expansion of HCV patient care within existing service providers: capacity needs to be greatly increased to accommodate increases in the size of the diagnosed population. The PWID population also poses challenges regarding linkage to care after diagnosis and especially with retention in care. In Australia, progression through the care cascade was historically subject to high attrition, as indicated by the small percentage (9%) of Australia's chronically infected PWID treated by the end of 2015 [29] .
Limitations
To estimate the main indicators for measuring the achievement of WHO 2030 targets-the cumulative percent of patients initiated on treatment and the reduction in annual number of ESLD deaths-we set the baseline year to 2015 (per WHO [1] ). The prevalent number of living chronically infected individuals and number of ESLD deaths in 2015 are model-based estimates, so evaluation of target achievement depends on the validity of these figures. Finally, as no Malaysian incidence data are available, we needed to make modelling assumptions regarding continuing transmission; thus, the expected annual growth of the HCV-infected population means that evaluation with respect to 2015 may seem overly successful.
Conclusions
In Malaysia, the economic and disease burden attributable to HCV-related liver disease is projected to increase substantially over the next two decades. This is partly due to ongoing viral transmission, but the majority of the direct costs will be incurred by those infected in the 1990s or earlier who are now progressing to advanced disease stages. Although highly effective DAAs are available at affordable prices, annual uptake of treatment must be scaled up massively to significantly reduce the projected disease burden. To meet the WHO GHSS targets of 90% diagnosed and 80% of diagnosed patients treated by 2030, treatment uptake scale-up would have to be steeper than currently considered viable and depends on an enormous increase in screening/ diagnosis and the provision of treatment and follow-up services. Both direct patient care/management costs and screening programme costs are essential for comparing the total economic burden across scenarios. These projections highlight the urgent need for better HCV control/preventive measures and for supportive policies that lead to improved case finding and consequent referral to care and initiation on effective antiviral therapy.
Data Availability Statement
All parameter values/distributions for the natural history component and all patient management/care and drug treatment costs for the economic component of the model are provided in the main paper and the ESM. The R/JAGS code to run each scenario can be obtained from the first author.
